mrctechnology.org articles

News : New drug discovery collaborations with Queen Mary University of London launched

Two new collaborations with Prof Mauro Perretti at the William Harvey Research Institute, Queen Mary University of London (QMUL) launched

News : New ACTH-dependent Cushing’s Syndrome drug discovery project launched

Collaboration launched with Prof Adrian Clark and Dr Li Chan at the William Harvey Research Institute, Queen Mary University of London

News : MRCT announce second drug discovery collaboration with University of Bristol

MRCT have recently launched a second collaboration with the University of Bristol in the area of pain medicine.

News : MRCT has published a paper in the latest issue of Bioorganic & Medicinal Chemistry Letters

Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis

News : OPT used in research to measure changes in tumour volume

Researchers at the Breakthrough Breast Cancer Research Unit have used OPT imaging to measure changes in tumour volume.

Press Release : Mount Sinai School of Medicine and MRC Technology to collaborate on monoclonal antibody production and humanization

Mount Sinai Medical Center and MRC Technology have reached an agreement to collaborate on the development of monoclonal antibodies for commercialization as drugs to control infection and treat diseases.

Press Release : MRC Technology Launches Research Grant Terms Approval Service

MRC Technology announces the launch of its research grant terms approval service, with the MS Society receiving the first review.

Press Release : Phosphate Therapeutics acquires novel phosphate binder (PT20) from the Medical Research Council and secures development funding from Inventages Venture Capital for Compound’s Phase 2 Development

Phase 2 ready phosphate binder for treatment of hyperphosphataemia

News : Barbara Saxty co-author on Nature Communications paper

Barbara Saxty has co-authored a Nature Communications paper entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.

News : MRCT-supported Research Fellow vacancy at University of Leicester

The University of Leicester is recruiting for an MRCT-supported Research Fellow

News : New drug discovery collaboration with University of Bristol launched

MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.

News : New cancer therapeutic antibody project launched

MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.

News : Aptuscan acquired by Avacta

Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.

Press Release : MRC Technology to manage intellectual property for AICR

MRC Technology to oversee and manage intellectual property arising from AICR-funded projects

News : MRCT to manage AICR IP

MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.

News : Fuelling innovative discoveries and driving crucial research onto the market

Dave Tapolczay has spoken to Research Media's International Innovation about fuelling innovative discoveries and driving crucial research onto the market

News : Crowd sourcing in drug discovery

MRCT's Justin Bryans contributes to Nature Reviews Drug Discovery article on crowd sourcing in drug discovery

News : The art of turning ideas into products

MRCT featured in Financial Times article on university tech transfer

News : Images created using OPT scanner win Wellcome Image Award 2011

2 images created using OPT scanner win Wellcome Image Awards 2011

News : New Director of Corporate Partnerships appointed

Mike Johnson appointed as new Director of Corporate Partnerships